Study

Etiology

Patient Characteristics

N

Study Design

Main findings *

Shaddy et al.
2007 [64]

Dilated CM and  systemic RV

Age < 13 yrs LVEF 27% NYHA class II & III

161

Multicenter RCT
Carvedilol vs. Placebo for 8 months

No difference. In patients with systemic LV, a trend towards improvement was noted however

Doughan et al.
2007 [65]

D-TGA (atrial baffle)

Adults RVEF 35%
NYHA class I to  III

60

Retrospective study.
4 months
Carvedilol or Metoprolol for 

Beneficial effect: ↓NYHA class especially if pacemaker or initial NYHA class III
Prevents further chamber dilatation

Josephson et al.
2006 [66]

D-TGA (atrial baffle)

Adults
NYHA mainly class II
RV diameter 41.5 mm

8

Retrospective study. Median 
FU of  3 yrs
Carvedilol Metoprolol, Sotalol

Beneficial effect: ↓ NYHA class in 5 patients

Giardini et al.
2007 [67]

D-TGA (atrial baffle)
L-TGA

Age > 18 yrs
NYHA class II & III
RVEF= 34%

8

Single arm prospective
Carvedilol
for 12 months

Beneficial effect: ↓ RVED volume by 6%, ↑RVEF 6% ‡. No change in peak VO2.

Norozi et al.
2007 [68]

Tetralogy of Fallot

NYHA I and II
Adults
LVEF= 57%
CI = 3.8 L/min/m2

33

RCT
Bisoprolol vs. placebo for 6 months

No difference in peak VO2, RVEF,  ventricular volumes, NYHA class

*Unless otherwise specified, the results refer to statistically significant findings (p<0.05). The changes reported refer to relative changes in mean effect size or when indicated by ‡ changes in absolute effect size. Abbreviations as in previous tables. RVED indicates RV end-diastolic volume
Table 4: Beta blockade in patients with congenital heart disease.